QTNT - Earnings announcements

MosaiQ™ Solution Commercial Execution: Extended IH Launch: $1.4 million MosaiQ bookings completed with $0.4 million in revenue in the first quarterDistribution Network: Ten agreements signed with more in process; First distributor network meeting held in Switzerland with 12 participantsTenders: The Company continues to actively participate in and prepare for all available tenders Transfusion Diagnostics: Extended Immunohematology (IH) microarray on track for US FDA submission by year-end; Extended Serological Disease Screening (SDS) microarray panel on-track for EU commercial launch in calendar year 2023; InfYnity partnership enriches infectious disease immunoassay microarray offeringClinica

JERSEY, Channel Islands, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal first quarter ended June 30, 2022 will be released before market open on Tuesday, August 9, 2022. Title:Quotient First Quarter Fiscal 2023 Financial Results and Conference Call Speakers:Manuel O. Méndez, Chief Executive OfficerAli J. Kiboro, Chief Financial OfficerDate:Tuesday, August 9, 2022Time:8:30am ET/ 14:30 CETConference Call Dial-in Details:International: 201-689-8560Switzerland: 0800 835 525United Kingdom: 0800 756 3429US: 877-407-0784Conference ID: 13731396Webcast:Webcast Link - Click HereQuot

Financial Position Amended Secured Notes: Reduces the company's cash obligations by approximately $93 million over the next 36 monthsAnnounces Public Equity Offering: Improving liquidity runwayFY 2022 Revenue of $38.5 Million$83.2 million in cash and investments as of March 31, 2022  MosaiQ™ Solution Commercial Execution: Extended IH Launch: Commercialization is underway; $1.4 million of MosaiQ orders in Q1 FY2023; Multiple MosaiQ instruments shipped to customersTenders: Actively engaged in Immunohematology (IH) donor tenders; 20 European IH donor tender submissions expected in the next 18 monthsDistribution Network: 9 international agreements in place and expanding global distribution ne

Pre-announces FY 2022 revenue of $38.5 millionSecured $1.4 million of orders in Q1 FY23 for recently CE Marked Extended IH MosaiQ Solution$83.2 million in cash and investments as of March 31, 2022 JERSEY, Channel Islands, June 21, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that it is rescheduling the release of its financial results for the fourth quarter and full year 2022 ended March 31, 2022. The Company will release these financial results and host a conference call before market open on Friday, June 24, 2022. Quotient expects to report reagent business generated product sales of $9.8 million in the fourth quarter

JERSEY, Channel Islands, June 17, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal fourth quarter and full year ended March 31, 2022 will be released before market open on Wednesday, June 22, 2022. Title:Quotient Fourth Quarter and Full Year 2021 Financial Results and Conference Call  Speakers:Manuel O. Méndez, Chief Executive OfficerAli J. Kiboro, Chief Financial Officer  Date:Wednesday, June 22, 2022Time:8:00am ET/ 14:00 CET  Conference CallDial-in Details:International: 201-689-8560Switzerland: 0800 835 525United Kingdom: 0800 756 3429US: 877-407-0784Conference ID: 13729874  Webcast:We

MosaiQ™ Solution: Transfusion Diagnostics: The Notified Body completed the assessment of the Company's technical dossier and has advised that it will recommend the MosaiQ Expanded Immunohematology (IH) microarray for CE marking approval;Commercial Execution: In anticipation of CE marking, the Company's Commercial team is preparing to submit more than 20 tender responses within the EU over the next 18-24 months; At the same time, the Company is actively pursuing distribution partnerships in the EU, Middle East and Africa;Manufacturing & Operations: Scale up in progress to support the anticipated MosaiQ commercial launch; Finalized decision on second manufacturing line to meet targeted market

JERSEY, Channel Islands, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal third quarter ended December 31, 2021 will be released before market open on Tuesday, February 8, 2022. Quotient will host a conference call to discuss its third quarter financial results at 8:00am Eastern Time the same day. Participants may access the conference call by dialing 1-877-407-0784 (US) or 1-201-689-8560 (International), using conference ID 13725727. The conference call will be webcast live on the Company's website at www.quotientbd.com. A replay of the conference call will be available through

Executive Leadership Team: Recent new hires will support anticipated rapid growth and help lead future development MosaiQ™ Solution Transfusion Dx: The Expanded Immunohematology CE regulatory dossier has been submitted with 20 specificities; and Expanded Serological Disease Screening immunoassay microarray is progressing towards field trials expected to begin in Q2 CY 2022Commercial Execution: Six MosaiQ tender evaluations are in progress; Multiple distributors identified with more than 100 qualified customer targets Potential New Market Segments: Initiated an R&D program to develop Clinical Diagnostic solutions, focusing first on potential candidates for the $2B Allergy IVD market. Quotie

JERSEY, Channel Islands, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced that financial results for its fiscal second quarter ended September 30, 2021 will be released before market open on Tuesday, November 9, 2021. Quotient will host a conference call to discuss its second quarter financial results at 8:00 a.m. Eastern Time the same day. Participants may access the call by dialing 1-877-407-0784 in the U.S. or 1-201-689-8560 outside the U.S. The access code is 13724411. The conference call will be webcast live on the Company's website at www.quotientbd.com. A replay of this conference call will be a

MosaiQ™ Solution Transfusion Dx: Latest data confirms performance of MosaiQ Expanded IH; Expanded SDS microarray demonstrates excellent performanceCommercial Execution: Significant progress made with several customer evaluations scheduled; 25 separate distributor contacts establishedNew Market Segments: Successful proof of concept project further indicates full extent of MosaiQ by Quotient solution Alba by Quotient: Revenues within guidance; Key future growth drivers identified and being pursuedFinancial Position: Significantly strengthened balance sheet JERSEY, Channel Islands, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (Quoti